Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-028328
Filing Date
2025-02-27
Accepted
2025-02-27 06:43:06
Documents
72
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K nuvl-20241231.htm   iXBRL 10-K 3145122
2 EX-19.1 nuvl-ex19_1.htm EX-19.1 253894
3 EX-23.1 nuvl-ex23_1.htm EX-23.1 3307
4 EX-31.1 nuvl-ex31_1.htm EX-31.1 17217
5 EX-31.2 nuvl-ex31_2.htm EX-31.2 17478
6 EX-32.1 nuvl-ex32_1.htm EX-32.1 8039
7 EX-32.2 nuvl-ex32_2.htm EX-32.2 8483
8 GRAPHIC img240582223_0.jpg GRAPHIC 173738
9 GRAPHIC img240582223_1.jpg GRAPHIC 580460
10 GRAPHIC img240582223_2.jpg GRAPHIC 718297
11 GRAPHIC img240582223_3.jpg GRAPHIC 102948
  Complete submission text file 0000950170-25-028328.txt   13926293

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20241231.xsd EX-101.SCH 1304283
75 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20241231_htm.xml XML 1473976
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40671 | Film No.: 25672731
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)